report revenu line pre-announce street
non-gaap ep line street estim manag
lower report guidanc follow cynosur divestitur reiter
confid core busi believ divestitur enabl manag
substanti grow margin accordingli remain overweight increas price
target base ep
result report cc organ cc revenu growth
street breast health grew cc street
diagnost grew cc street gyn surgic grew
cc street skelet health grew cc street
medic aesthet cynosur declin cc street
adj gross margin declin bp due cynosur perform
product mix non-gaap ep street
busi updat upbeat diagnost perform segment
driven strong molecular growth manag reiter robust
intern opportun manag disappoint cynosur perform
quarter versu expect flat growth confid divestitur
remov overhang allow team focu core busi manag
reiter tuck-in strategi said primarili look deal
diagnost surgic given recent deal breast health
 guidanc lower revenu cc growth guidanc
primarili due cynosur manag expect organ
revenu grow ex-cynosur manag expect revenu
street follow cynosur
divestitur adjust divestitur manag increment increas core
growth like due faster expect perform ssi opinion holog
increas non-gaap ep guidanc street
manag guid revenu street non-gaap
ep street
stock continu believ cynosur divestitur
lead improv margin growth core busi encourag
growth molecular accordingli remain overweight target
new product adopt fda regul competit acquisit integr
inc focus provid health care product women
ep
debt total capit
ep exclud one-tim item includ sbc
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
thousand
product sale
good sold product sale
compani report piper sandler co current disclosur inform compani locat
page
